In a study performed to determine which regions of the human T-cell lymphotrophic virus
type III (HTLV-III) may represent vaccine candidates to prevent the acquired immune …

Two synthetic peptides containing amino acid sequences analogous to the envelope
glycoprotein of human T‐lymphotropic virus (HTLV) type III (HTLV‐III) and lymphadenopathy …

Antibodies from the serum of patients with the acquired immune deficiency syndrome (AIDS)
or with the AIDS-related complex and from the serum of seropositive healthy homosexuals …

Immunization with either an Escherichia coli recombinant segment of the human T-cell
lymphotropic virus (HTLV-III/LAV) envelope protein (gp120) or with deglycosylated gp120 …

In this study, two glycoproteins (gp160 and gp120) that are encoded by human T-cell
lymphoma virus type III (HTLV-III) were the antigens most consistently recognized by …

Human T-lymphotropic virus type III (HTLV-III) or lymphadenopathy-associated virus (LAV) is
tropic for human T cells with the helper-inducer phenotype, as defined by reactivity with …

The envelope (env) and structural (gag) gene products of human T-cell leukemia
(lymphotropic) virus type III were identified by immunoaffinity chromatography …

The sequence of the envelope glycoprotein gene of type II human T lymphotropic virus
(HTLV) is presented. The predicted amino acid sequence is similar to that of the …

A newly identified protein from HTLV-III/LAV, the virus implicated as the etiologic agent of the
acquired immune deficiency syndrome, was studied. This protein, which has a molecular …

Human T-cell lymphotropic virus type III (HTLV-III), the causative agent of the acquired
immune deficiency syndrome (AIDS), was recently isolated and its genomic structure …